Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 279
Filter
1.
Rev. chil. neuro-psiquiatr ; 58(1): 61-65, mar. 2020. tab
Article in Spanish | LILACS | ID: biblio-1115471

ABSTRACT

Resumen Se han descrito una serie de reacciones adversas asociadas a antipsicóticos, entre las que destacan las reacciones adversas hematológicas propias de algunos antipsicóticos atípicos. Las más renombradas han sido clásicamente las discrasias sanguíneas asociadas al uso de olanzapina. En este trabajo nos enfocamos en una reacción adversa poco común: eosinofilia en un paciente esquizofrénico paranoide usuario de olanzapina, situación documentada en contadas publicaciones a lo largo de la historia de uso de este medicamento. Se trata de una reacción adversa infrecuente, y por lo mismo poco conocida y estudiada.


Many adverse effects of antipsychotic drugs have been described, among which hematologic adverse effects stand out. Classically, blood discrasias have been associated to the use of olanzapine. On this paper we will focus on an uncommon adverse reaction: eosinophilia in a patient diagnosed with a paranoid schitzophrenia, who had been using olanzapine. There have been just a few reported cases of eosinophilia secondary to the use of olanzapine, which makes this an infrequent, rarely known and even less studied adverse reaction.


Subject(s)
Humans , Male , Adult , Schizophrenia , Antipsychotic Agents , Eosinophilia , Olanzapine
2.
HIV Med ; 18(10): 782-786, 2017 11.
Article in English | MEDLINE | ID: mdl-28671337

ABSTRACT

OBJECTIVES: Cobicistat seems to have a low rate of adverse events compared with ritonavir. METHODS: This restrospective observational study to evaluated changes in lipid parameters and the percentage of subjects with dyslipidemia in virologically suppressed HIV-infected patients who were receiving a regimen containing darunavir/ritonavir and were then switched from ritonavir to cobicistat, carried out from December 2015 to May 2016, included 299 HIV-1-infected patients who were on stable antiretroviral treatment including darunavir/ritonavir (monotherapy, bitherapy or triple therapy for at least 6 months) and were then switched from ritonavir to cobicistat. Lipid parameters, as well as plasma HIV-1 RNA and CD4 cell counts, were recorded at baseline just before the switch, and 24 weeks after the switch. Patients were stratified according to the presence of hypercholesterolaemia [baseline total cholesterol > 200 mg/dL and/or low-density lipoprotein (LDL) cholesterol > 130 mg/dL] or hypertriglyceridaemia (baseline triglyceride levels > 200 mg/dL). RESULTS: Two hundred and ninety-nine patients were enrolled in the study. Fifty-two per cent of the total study population showed dyslipidaemia at baseline. All patients maintained HIV-1 RNA ≤ 50 HIV-1 RNA copies/mL at week 24. No statistically significant changes were seen in CD4 T-cell count from baseline to week 24 [654 (298) to 643 (313) cells/µL; P = 0.173]. When patients were stratified according to the presence of hypercholesterolaemia at baseline (n = 124), significant changes were observed in total cholesterol (P < 0.001), LDL cholesterol (P = 0.047), high-density lipoprotein (HDL) cholesterol (P = 0.002) and triglyceride levels (P = 0.025), and when they were stratified according to the presence of hypertriglyceridaemia at baseline (n = 64), changes from baseline to week 24 in triglyceride level were statistically significant [median (interquartile range) 352 (223, 389) mg/dL at baseline and 229 (131, 279) mg/dL at week 24; P < 0.001]. CONCLUSIONS: Cobicistat as a booster of darunavir in HIV-infected subjects had a beneficial effect on the lipid profile in patients with hypercholesterolaemia or hypertrigliceridaemia at baseline.


Subject(s)
Anti-HIV Agents/administration & dosage , Cobicistat/adverse effects , Drug Substitution , Dyslipidemias/chemically induced , HIV Infections/drug therapy , Ritonavir/adverse effects , Triglycerides/blood , Adult , CD4 Lymphocyte Count , Cobicistat/administration & dosage , Female , HIV-1/isolation & purification , Humans , Male , Middle Aged , RNA, Viral/blood , Retrospective Studies , Ritonavir/administration & dosage , Treatment Outcome , Viral Load
3.
J Antimicrob Chemother ; 72(7): 2049-2054, 2017 07 01.
Article in English | MEDLINE | ID: mdl-28369542

ABSTRACT

Background: The effect of ART on endothelial cell function is incompletely characterized. Methods: We performed a 24 week prospective, case-control and comparative pilot study of ART-naive HIV-infected patients who started a darunavir- or rilpivirine-based regimen, matched with non-HIV-infected volunteers, to compare changes at week 24 from baseline in levels of circulating endothelial cells (CECs), endothelial progenitor cells (EPCs) and circulating angiogenic cells, as well as changes in immune-activation markers. Results: The study population comprised 24 HIV-infected patients and 24 non-infected volunteers. Both HIV groups completely suppressed viraemia. HIV-infected patients had higher levels of activation markers than the control group in CD8 T cells at baseline; these decreased after 24 weeks of treatment, but without reaching the levels of the control group. No statistical differences in immune activation were seen between the darunavir and rilpivirine groups. Levels of CECs were higher and levels of EPCs and circulating angiogenic cells were lower in HIV-infected patients than in the control group, although these parameters were similar between the darunavir group and the control group, but not the rilpivirine group, at week 24. An unfavourable association was observed between rilpivirine, age and increased number of CECs. Conclusions: Restoration of circulating levels of EPCs and CECs in darunavir-treated patients was greater than in those treated with rilpivirine, suggesting ongoing endothelial repair mechanisms.


Subject(s)
Anti-HIV Agents/therapeutic use , Endothelial Cells/drug effects , Endothelial Cells/physiology , HIV Infections/drug therapy , Adult , Anti-HIV Agents/adverse effects , Case-Control Studies , Darunavir/adverse effects , Darunavir/therapeutic use , Endothelial Cells/immunology , Female , HIV Infections/immunology , HIV-1/drug effects , Humans , Male , Middle Aged , Pilot Projects , Prospective Studies , Reverse Transcriptase Inhibitors/therapeutic use , Rilpivirine/adverse effects , Rilpivirine/therapeutic use , Viral Load/drug effects , Viremia/drug therapy
4.
HIV Med ; 16(7): 441-8, 2015 Aug.
Article in English | MEDLINE | ID: mdl-25944411

ABSTRACT

OBJECTIVES: Given the need for easily managed treatment of osteoporosis in HIV-infected patients, we evaluated the efficacy and tolerability of two doses of zoledronate, by comparing three groups of patients: those with annual administration, those with biennial administration (one dose in 2 years) and a control group with no administration of zoledronate. METHODS: We randomized (2:1) 31 patients on antiretroviral therapy with low bone mineral density (BMD) to zoledronate (5 mg administered intravenously; 21 patients) plus diet counselling and to a control group (diet counselling; 10 patients). At week 48, patients treated with zoledronate were randomized again to receive a second dose (two-dose group; n = 12) or to continue with diet counselling only (single-dose group; n = 9). Changes in lumbar spine and hip BMD and bone turnover markers were compared. RESULTS: The median percentage change from baseline to week 96 in L1-L4 BMD was -1.74% [interquartile range (IQR) -2.56, 3.60%], 7.90% (IQR 4.20, 16.57%) and 5.22% (IQR 2.02, 7.28%) in the control, two-dose and single-dose groups, respectively (P < 0.01, control vs. two doses; P = 0.02, control vs. single dose; P = 0.18, two doses vs. single dose). Hip BMD changed by a median of 2.12% (IQR -0.12, 3.08%), 5.16% (IQR 3.06, 6.74%) and 4.47% (IQR 1, 5.58%), respectively (P = 0.04, control vs. two doses; P = 0.34, two doses vs. single dose). No differences between the two-dose and single-dose groups were detected in bone markers at week 96. CONCLUSIONS: The benefits for BMD of a single dose of zoledronate in 2 years may be comparable to those obtained with two doses of the drug after 96 weeks, although this study is insufficiently powered to exclude a real difference. Future studies should explore whether biennial administration of zoledronate is a useful alternative in the treatment of osteoporosis in HIV-infected patients.


Subject(s)
Absorptiometry, Photon , Antiretroviral Therapy, Highly Active/adverse effects , Bone Density Conservation Agents/administration & dosage , Bone Density/drug effects , Diphosphonates/administration & dosage , HIV Infections/drug therapy , Imidazoles/administration & dosage , Osteoporosis/chemically induced , Biomarkers/blood , Bone Remodeling/drug effects , Directive Counseling , Dose-Response Relationship, Drug , Drug Administration Schedule , Feeding Behavior , Female , Humans , Lumbar Vertebrae/metabolism , Male , Middle Aged , Osteoporosis/physiopathology , Osteoporosis/therapy , Pelvic Bones/metabolism , Pilot Projects , Treatment Outcome , Zoledronic Acid
5.
Rev. ANACEM (Impresa) ; 7(3): 152-154, dic.2013.
Article in Spanish | LILACS | ID: lil-779305

ABSTRACT

En Chile aún existe la salmonelosis como causal de enfermedad entérica, prevaleciendo el serotipo Enteritidis. En sepsis neonatal el germen más frecuente es Streptococcus grupo B (SGB); los bacilos Gram negativos entéricos ocupan el segundo lugar. La Salmonella spp. es infrecuente. Las vías de transmisión pueden ser hematógena, canal del parto, ascendente u horizontal. CASO CLÍNICO: Mujer sana, 31 años, embarazo de 39 semanas. Cultivo de SGB negativo. Presenta cuadro diarreico el día previo al parto, el cual fue vaginal, dilatación de cuatro horas, expulsivo de 15 minutos, líquido amniótico claro, destaca temperatura (T°) intraparto de 38,3°C. Recién nacido (RN)sexo masculino, adecuado para la edad gestacional, Apgar 9/9,con T° rectal 38,1°C al nacer. Al segundo día de vida presenta deposiciones líquidas verdosas con estrías de sangre, descenso de peso de 10,6 por ciento (367,82 gr) y T° rectal 37,7°C. Ingresa a neonatología, destacando Proteína C Reactiva elevada de 2,7 mg/dL. Por persistir cuadro se solicitan cultivos previo a antibioterapia con Ampicilina y Gentamicina. Test APT-Downey positivo, cultivo orina y líquido cerebroespinal negativos, hemocultivo y coprocultivo positivo a Salmonella tipo D subtipo Panamá. Evoluciona favorablemente, es dado de alta al noveno día con diagnóstico de sepsis por Salmonella tipo D connatal. Coprocultivo de madre positivo para Salmonella. DISCUSIÓN: La prevalencia de infecciones por Salmonella se ha incrementado en neonatos. Es importante realizar prevención durante el embarazo además de un diagnóstico y tratamiento precoz. Se debe considerar este agente según factores de riesgo y como diagnóstico diferencial de hemorragia digestiva baja en el RN...


Salmonella infections are still a cause of entericdisease in Chile, with a predominance of the Enteritidis serotype. In neonatal sepsis the most frequent etiology is Group B Streptococcal (GBS) infection; enteric Gram-negative bacilli occupy second place. Salmonella spp. is infrequent. The transmission routes can be hematogenous, by birth canal, vertical, or horizontal. CASE REPORT: Healthy 31 year old female, 39 week pregnancy. Negative GBS culture. Presents with diarrhea the day before labor, with vaginal delivery, four hour dilation period,15 minute expulsion period, clear amniotic fluid, intra delivery temperature (T°) of 38.3°C. Male, adequate for gestational age newborn, Apgar 9/9, with rectal T° of 38.1°C at birth. During second day of life, presents green liquid stools with blood streaks, weight loss of 10.6 percent (367.82 gr), and rectal T° of 37.7°C. Patient is admitted to neonatology service, where he presents elevated C-Reactive Protein of 2.7 mg/dL. Cultures were taken due to persistent findings, before antibiotic therapy with Ampicillinand Gentamicin. Positive APT-Downey test, negative urine and cerebrospinal fluid cultures, positive blood and stool cultures for type D, subtype Panama Salmonella. Favorable evolution, discharged on day nine with diagnosis of sepsis due to connatal type D Salmonella. Mother’s stool culture is positive for same bacteria. DISCUSSION: The prevalence of Salmonella infections has increased in neonates. Prevention during pregnancy, along with early diagnosis and treatment, are important. This agent should be considered according to risk factors, and as a differential diagnosis of lower gastrointestinal bleeding in newborns...


Subject(s)
Humans , Male , Adult , Female , Pregnancy , Infant, Newborn , Pregnancy Complications, Infectious/diagnosis , Pregnancy Complications, Infectious/microbiology , Salmonella Infections/diagnosis , Salmonella Infections/microbiology , Ampicillin/therapeutic use , Anti-Bacterial Agents/therapeutic use , Pregnancy Complications, Infectious/drug therapy , Gentamicins/therapeutic use , Intensive Care, Neonatal , Salmonella Infections/drug therapy , Salmonella/isolation & purification
6.
Int. j. morphol ; 31(2): 672-680, jun. 2013. ilus
Article in Spanish | LILACS | ID: lil-687123

ABSTRACT

La dimensión vertical es una medida aproximada de las relaciones fisiológicas intermaxilares. Su obtención es un proceso sensible y metódico que produce efectos craneofaciales colaterales cuando es erróneamente lograda. Los conceptos individualistas de su obtención deben ser cambiados e interiorizados de una manera colectiva debido a la complejidad de la dinámica masticatoria que exige una perspectiva más amplia de esta noción. La correspondencia entre la dimensión vertical y lo funcional-disfuncional cráneo-cervical es innegable y va mas allá de una relación exclusivamente dental. Esta revisión busca situar al lector en una realidad estomatognática y no solo odontológica, que exige mayores esfuerzos y un cambio de perspectiva en la conceptualización de la importancia de la dimensión vertical en el normal funcionamiento del sistema estomatognático y de estructuras vecinas en el paciente edentado.


Vertical dimension is an approximate measure of the physiological inter-maxillary relations. Its register is a sensitive and methodical process with craniofacial side effects when wrongly achieved. Single concepts for vertical dimension register should be changed and understood in a collective manner. The complexity of the masticatory dynamics requires a broader view of this notion. The correspondence between the vertical dimension and the functional-dysfunctional cranio-cervical relations is undeniable and goes beyond an exclusively dental relation. This review seeks to place the reader in a stomatognathic functional perspective, which requires greater efforts of the prosthodontics operator. Normal functioning of the stomatognathic system and surrounding structures in the edentulous patient depends on the conceptualization about the importance of vertical inter-maxillary relations.


Subject(s)
Humans , Mouth, Edentulous/pathology , Hearing Loss , Pain, Referred , Tinnitus , Vertical Dimension , Vertigo
7.
Rev. clín. esp. (Ed. impr.) ; 213(2): 88-96, mar. 2013.
Article in Spanish | IBECS | ID: ibc-110563

ABSTRACT

Introducción. Los objetivos fueron: a) describir la mortalidad y sus variables asociadas en la neumonía aguda comunitaria (NAC) a Streptococcus pneumoniae (S. pneumoniae); b) identificar aspectos terapéuticos a mejorar; c) identificar los principales serotipos de S. pneumoniae, y d) conocer la cobertura potencial de la vacuna antineumocócica 23 valente. Material y método. Criterio de inclusión: NAC en pacientes mayores de 16 años. Se consideró NAC neumocócica si al ingreso hospitalario se aisló S. pneumoniae desde la sangre y/o se detectó la presencia de antígeno neumocócico capsular en orina. Criterios de exclusión: negativa al consentimiento informado o infección neumocócica en el mes previo al ingreso. Resultados. Se identificaron 192 pacientes con edad promedio de 54,6±19,2 años. Comorbilidades más frecuentes: diabetes, EPOC e inmunodepresión. Se detectaron bacteriemias en 147 pacientes. Los serotipos más frecuentes fueron: 7F, 1 y 3. Ninguna cepa fue resistente a los betalactámicos y 8 (5,4%) a la eritromicina. Cobertura potencial de la vacuna antineumocócica 23 valente: 93%. Fallecieron 37 pacientes. Variables asociadas a la mortalidad: shock en las primeras 72h desde el ingreso al hospital (OR:7,51; IC 95%:2,94-19,17) y demora en el inicio de la antibioticorapia ≥6h (OR:2,47; IC 95%:1,00-6,17). Conclusiones. La mortalidad de la NAC neumocócica fue del 19,3%; las únicas 2 variables asociadas a ella fueron el shock séptico y la demora ≥6h en el inicio de la antibioticoterapia. Adicionalmente el mencionado retraso constituye el principal factor terapéutico a mejorarse en el futuro. El serotipo más frecuente fue el 7F. La cobertura potencial de la vacuna 23 valente es cercana al 90%(AU)


Introduction. The objectives of the present study were: a) to describe the mortality rate and its associated variables in community-acquired pneumoniae (CAP) due to Streptococcus pneumoniae (S. pneumoniae), b) to identify therapeutic issues to improve and c) to describe the main serotypes of S. pneumoniae and d) to know the potential coverage of antipneumococcal 23-valent vaccine. Materials and methods. Inclusion criteria were age >16 years-old hospitalized due to PAC. Pneumococcal PAC etiology was considered if S. pneumoniae was isolated from blood culture and/or positive capsular urinary antigen detected at hospital admission. Exclusion criteria were patients who refused participation and/or pneumococcal infection diagnosis was made within the last month before hospital admission. Results. A total of 192 patients were included, mean age 54.6±19.2 years. The most frequent comorbidities were diabetes, COPD and immunosupression. There were 147 patients with bacteremia. The most frequent serotypes were 7F, 1 and 3. Beta-lactamic resistant microorganisms were not identified and only 8 (5.4%) strains were erythromycin-resistant. Potential anti-pneumococcal 23-valent vaccine coverage was 93%. Thirty seven patients died. Variables associated with mortality were shock within the first 72h of hospital admission (OR:7.51; 95% CI:2.94-19.17) and antibiotic delay ≥6h (OR:2.47; 95% CI:1.00-6.17). Conclusions. Pneumococcal pneumonia mortality was 19.3%. Septic shock and antibiotic delay ≥6h since hospital admission were associated with hospital mortality. The most frequent serotype was 7F. The potential anti-pneumococcal vaccine coverage is almost 90%(AU)


Subject(s)
Humans , Male , Female , Adolescent , Young Adult , Adult , Middle Aged , Aged , Aged, 80 and over , Pneumonia/epidemiology , Pneumonia/prevention & control , Pneumococcal Infections/epidemiology , Streptococcus pneumoniae/isolation & purification , Community-Acquired Infections/epidemiology , Community-Acquired Infections/prevention & control , Pneumococcal Infections/microbiology , Streptococcus pneumoniae , Odds Ratio , Confidence Intervals , Prognosis
8.
Rev Clin Esp (Barc) ; 213(2): 88-96, 2013 Mar.
Article in English, Spanish | MEDLINE | ID: mdl-23178082

ABSTRACT

INTRODUCTION: The objectives of the present study were: (a) to describe the mortality rate and its associated variables in community-acquired pneumoniae (CAP) due to Streptococcus pneumoniae (S. pneumoniae), (b) to identify therapeutic issues to improve, (c) to describe the main serotypes of S. pneumoniae and (d) to know the potential coverage of antipneumococcal 23-valent vaccine. MATERIALS AND METHODS: Inclusion criteria were age >16 years-old hospitalized due to PAC. Pneumococcal PAC etiology was considered if S. pneumoniae was isolated from blood culture and/or positive capsular urinary antigen detected at hospital admission. Exclusion criteria were patients who refused participation and/or pneumococcal infection diagnosis was made within the last month before hospital admission. RESULTS: A total of 192 patients were included, mean age 54.6 ± 19.2 years. The most frequent comorbidities were diabetes, COPD and immunosupression. There were 147 patients with bacteremia. The most frequent serotypes were 7F, 1 and 3. Beta-lactamic resistant microorganisms were not identified and only 8 (5.4%) strains were erythromycin-resistant. Potential anti-pneumococcal 23-valent vaccine coverage was 93%. Thirty-seven patients died. Variables associated with mortality were shock within the first 72 h of hospital admission (OR: 7.51; 95% CI: 2.94-19.17) and antibiotic delay ≥6 h (OR: 2.47; 95% CI: 1.00-6.17). CONCLUSIONS: Pneumococcal pneumonia mortality was 19.3%. Septic shock and antibiotic delay ≥6 h since hospital admission were associated with hospital mortality. The most frequent serotype was 7F. The potential anti-pneumococcal vaccine coverage is almost 90%.


Subject(s)
Pneumonia, Pneumococcal/mortality , Streptococcus pneumoniae/classification , Adolescent , Adult , Aged , Aged, 80 and over , Bacterial Typing Techniques , Community-Acquired Infections/diagnosis , Community-Acquired Infections/microbiology , Community-Acquired Infections/mortality , Community-Acquired Infections/therapy , Drug Resistance, Bacterial , Female , Follow-Up Studies , Hospitalization , Humans , Logistic Models , Male , Middle Aged , Pneumococcal Vaccines , Pneumonia, Pneumococcal/diagnosis , Pneumonia, Pneumococcal/microbiology , Pneumonia, Pneumococcal/therapy , Prospective Studies , Streptococcus pneumoniae/isolation & purification , Streptococcus pneumoniae/physiology , Treatment Outcome , Uruguay , Young Adult
9.
Rev. chil. obstet. ginecol ; 77(6): 465-470, 2012.
Article in Spanish | LILACS | ID: lil-665597

ABSTRACT

Hasta hace algunos años en las mujeres sometidas a histerectomía por patología benigna, que tuvieran 45 o más años, se efectuaba de regla una salpingoooforectomía (SOB) bilateral, como prevención de cáncer de ovario. Esto está actualmente en discusión. Hay dos grandes estudios de cohortes poblacionales y un estudio prospectivo observacional que analizan los efectos adversos cardiovasculares y el cáncer de ovario en mujeres sometidas a SOB. Basados en estos análisis y otros datos de la literatura, se pueden plantear algunas conclusiones. En mujeres premenopáusicas y hasta los 50 años la conducta óptima es preservar los ovarios, entre 51 y 65 años no está claro que lo mejor sea extirparlos y en mayores de 65 aún no se ha probado efectos deletéreos a raíz de la intervención.


The age to perform prophylactic oophorectomy at the time of hysterectomy for benign conditions is being actually discussed. Two population based cohorts studies and one prospective observational study evaluate cardiovascular disease and ovarian cancer with a history of oophorectomy. Some conclusions can be drawn. Until 50 years or premenopausal women, ovarian conservation should be the norm, between 51 and 65 there are no clear indications for removal and in older than 65 no negative effects have been described.


Subject(s)
Humans , Adult , Female , Cardiovascular Diseases/etiology , Hysterectomy/adverse effects , Ovariectomy/adverse effects , Ovariectomy/methods , Menopause , Uterine Cervical Neoplasms/prevention & control , Ovariectomy , Patient Selection
11.
Antiviral Res ; 85(2): 403-8, 2010 Feb.
Article in English | MEDLINE | ID: mdl-19941906

ABSTRACT

BACKGROUND: Although efavirenz and lopinavir/ritonavir(r) are both recommended antiretroviral agents in antiretroviral-naïve HIV-infected patients, there are few randomized comparisons of their efficacy and tolerability. METHODS: A multicenter and randomized study was performed including 126 antiretroviral-naïve patients, randomly assigned to efavirenz+Kivexa (n=63) or lopinavir/r+Kivexa (n=63). Efficacy endpoints were the percentage of patients with HIV-RNA < or =50 copies/mL at week 48 and CD4 recovery. Safety was assessed by comparing toxicity and discontinuations. Statistical analyses were performed on an intention-to-treat (ITT) basis (Missing=Failure). RESULTS: At week 48, 56.7% of patients in the efavirenz and 63.2% in the lopinavir/r groups showed HIV-1 RNA <50 copies/mL (P=0.770) (intention-to-treat analysis; Missing=Failure). Only 1 (1.53%) patient from each group experienced virological failure. CD4 values increased in both groups (298 cells in the efavirenz group, P=0.001; 249 cells in the lopinavir/r group, P=0.002; P=0.126 between groups). HDL-cholesterol only increased in the efavirenz group (from 39+/-12 mg/dL to 49+/-11; P=0.001). Discontinuations were more frequent in the lopinavir/r group (36.5% versus 28.5%; P=0.193), but more patients with efavirenz interrupted due to toxicity (11.1% versus 6.3%); most of them were attributed to hypersensitivity reaction. CONCLUSIONS: Similar virological efficacy was observed for efavirenz and lopinavir/r, when administered with Kivexa in antiretroviral-naïve patients, while immunological improvement was slightly superior for efavirenz. The higher rate of discontinuation due to toxicity in the efavirenz group was related to a higher incidence of hypersensitivity reaction. Nowadays, the use of the new formulation of lopinavir/r and the HLA-B*5701 genotype test before starting abacavir should improve the safety profiles of these regimens.


Subject(s)
Anti-HIV Agents/therapeutic use , Benzoxazines/therapeutic use , HIV Infections/drug therapy , Pyrimidinones/therapeutic use , Ritonavir/therapeutic use , Adult , Alkynes , Anti-HIV Agents/adverse effects , Benzoxazines/adverse effects , CD4 Lymphocyte Count , Cyclopropanes , Dideoxynucleosides , Drug Combinations , Drug Hypersensitivity , Female , Humans , Lamivudine/adverse effects , Lopinavir , Male , Middle Aged , Pyrimidinones/adverse effects , RNA, Viral/blood , Ritonavir/adverse effects , Treatment Outcome , Viral Load , Withholding Treatment/statistics & numerical data
12.
Lasers Med Sci ; 25(6): 873-80, 2010 Nov.
Article in English | MEDLINE | ID: mdl-19763668

ABSTRACT

The purpose of this in vitro study was to compare the effects of a self-etch adhesive system and neodymium:yttrium-aluminum-garnet (Nd:YAG) laser application on the dentinal permeability of the furcation area of primary molars. After endodontic access, 39 extracted human deciduous molars were divided into three groups: control group (CG), no treatment; adhesive group (AG), self-etching adhesive was applied to the furcation area; laser group (LG), specimens were irradiated with Nd:YAG laser. To evaluate dentin permeability of the furcation area, we immersed the specimens in 0.5 % methylene blue dye for 4 h. Then, they were longitudinally sectioned into two halves and photographed. The images were analyzed by two qualified evaluators using TpsDig software to calculate the percentage of the dye penetration area in comparison with the total furcation area. Additional analyses by scanning electron microscopy (SEM) were performed. The analysis of variance (ANOVA), complemented by Student's t-test, showed that mean dye penetration in the LG was statistically significant lower than that in all the other groups (P < 0.05). The SEM analysis showed mostly dentinal tubules obliterated by smear layer in the CG; in the AG the smear layer was modified by the adhesive, and, in the LG, melted surfaces were observed. It can be concluded that the Nd:YAG laser was capable of reducing the dentinal permeability of the furcation area of deciduous molars.


Subject(s)
Dental Etching/methods , Lasers, Solid-State/therapeutic use , Low-Level Light Therapy/methods , Coloring Agents , Dental Cements/therapeutic use , Dentin/radiation effects , Dentin/ultrastructure , Humans , In Vitro Techniques , Methylene Blue , Microscopy, Electron, Scanning , Molar/radiation effects , Molar/ultrastructure , Permeability , Tooth, Deciduous/radiation effects , Tooth, Deciduous/ultrastructure
13.
Oncogene ; 27(17): 2430-44, 2008 Apr 10.
Article in English | MEDLINE | ID: mdl-17968310

ABSTRACT

The p160 nuclear receptor co-activators represent a family of molecules, which are recruited by steroid nuclear receptors as well as other transcription factors that are overexpressed in several tumors. We investigated the role of one member of this family on the sensitivity of cells to apoptosis. We observed that overexpression of the RAC3 (receptor-associated co-activator-3) p160 co-activator inhibits hydrogen peroxide-induced cell death in human embryonic kidney 293 (HEK293) cells. The mechanism involves the activation of anti-apoptotic pathways mediated through enhanced nuclear factor kappa B (NF-kappaB) activity, inhibition of caspase-9 activation, diminished apoptotic-inducing factor (AIF) nuclear localization and a change in the activation pattern of several kinases, including an increase in both AKT and p38 kinase activities, and inhibition of ERK2. Moreover, RAC3 has been found associated with a protein complex containing AIF, Hsp90 and dynein, suggesting a role for the co-activator in the cytoplasmatic nuclear transport of these proteins associated with cytoskeleton. These results demonstrate that there are several molecular pathways that could be affected by their overexpression, including those not restricted to steroid regulation or the nuclear action of co-activators, which results in diminished sensitivity to apoptosis. Furthermore, this could represent one mechanism by which co-activators contribute to tumor development.


Subject(s)
Apoptosis , Cytosol/metabolism , rac GTP-Binding Proteins/metabolism , Active Transport, Cell Nucleus , Apoptosis/drug effects , Apoptosis Inducing Factor/metabolism , Caspase 9/metabolism , Cell Line , Dyneins/metabolism , Enzyme Activation , Gene Expression Regulation , HSP90 Heat-Shock Proteins/metabolism , Humans , Hydrogen Peroxide/pharmacology , NF-kappa B/metabolism , Protein Binding , Protein Kinases/metabolism , Tacrolimus Binding Proteins/metabolism , rac GTP-Binding Proteins/genetics
15.
Acta Neurochir (Wien) ; 149(3): 239-44; discussion 244, 2007 Mar.
Article in English | MEDLINE | ID: mdl-17216372

ABSTRACT

BACKGROUND: During the last decade of the 20th century, continuous invasive PtO(2) recording has become a widely accepted and well-established means of monitoring patients with acute traumatic or spontaneous cerebral lesions. It is considered a safe and reliable tool for the detection of hypoxia in the ICU setting. However, while invasive measurements of intracranial pressure are being used both in the ICU and in standard diagnostic protocols for suspected chronic adult hydrocephalus the same has not yet happened in relation to PtO(2) recordings. METHODS: We report our experience with the first 10 patients who have been evaluated for suspected CAH applying a protocol that includes continuous cerebral PtO(2) measurements. The relationship between PtO(2) and ICP including a characteristic wave pattern (inverse waves) on the PtO(2) curve is analyzed and clinical and outcome data are recorded. RESULTS AND CONCLUSIONS: 1. PtO(2) recording in awake patients is safe and reliable. 2. The combination of classical Lundberg waves in the ICP recording with phases of inverse waves in the PtO(2) recording may predict good outcome after shunting. 3. The effect of concomitant conditions on the brain oxygenation can be estimated for individual patients and used as a negative predictor for surgical outcome. 4. Invasive intracranial monitoring is not free of potentially serious bleeding complications and can only be performed with risk enhancing factors (AVM/haemorrhagic diathesis) excluded.


Subject(s)
Hydrocephalus/diagnosis , Monitoring, Physiologic , Oxides , Platinum , Wakefulness/physiology , Aged , Aged, 80 and over , Chronic Disease , Female , Humans , Hydrocephalus/physiopathology , Hydrocephalus/surgery , Intensive Care Units , Intracranial Pressure/physiology , Male , Middle Aged , Monitoring, Physiologic/adverse effects , Neurologic Examination , Oxides/adverse effects , Platinum/adverse effects , Prognosis , Retrospective Studies , Risk Factors
16.
Acta Neurochir (Wien) ; 148(6): 673-5; discussion 675, 2006 Jun.
Article in English | MEDLINE | ID: mdl-16598409
18.
Eukaryot Cell ; 4(12): 1990-7, 2005 Dec.
Article in English | MEDLINE | ID: mdl-16339717

ABSTRACT

The results of this study describe the identification and characterization of the Toxoplasma gondii alpha-crystallin/small heat shock protein (sHsp) family. By database (www.toxodb.org) search, five parasite sHsps (Hsp20, Hsp21, Hsp28, Hsp29, and the previously characterized Hsp30/Bag1) were identified. As expected, they share the homologous alpha-crystallin domain, which is the key characteristic of sHsps. However, the N-terminal segment of each protein contains unique characteristics in size and sequence. Most T. gondii sHsps are constitutively expressed in tachyzoites and fully differentiated bradyzoites, with the exception of Hsp30/Bag1. Interestingly, by subcellular localization we observed that T. gondii sHsps are located in different compartments. Hsp20 is located at the apical end of the cell, Hsp28 is located inside the mitochondrion, Hsp29 showed a membrane-associated labeling, and Hsp21 appeared throughout the cytosol of the parasites. These particular differences in the immunostaining patterns suggest that their targets and functions might be different.


Subject(s)
Cell Compartmentation , HSP20 Heat-Shock Proteins/metabolism , HSP30 Heat-Shock Proteins/metabolism , Protozoan Proteins/chemistry , Protozoan Proteins/metabolism , Amino Acid Motifs , Amino Acid Sequence , Animals , Antibodies, Protozoan/biosynthesis , Cell Line , Cytosol/metabolism , DNA, Protozoan , DNA-Binding Proteins/chemistry , DNA-Binding Proteins/genetics , Expressed Sequence Tags , Fluorescent Antibody Technique, Indirect , Gene Expression , Genes, Protozoan , HSP20 Heat-Shock Proteins/chemistry , HSP20 Heat-Shock Proteins/genetics , HSP20 Heat-Shock Proteins/immunology , HSP20 Heat-Shock Proteins/isolation & purification , HSP30 Heat-Shock Proteins/chemistry , HSP30 Heat-Shock Proteins/genetics , HSP30 Heat-Shock Proteins/immunology , HSP30 Heat-Shock Proteins/isolation & purification , Humans , Immunohistochemistry , Life Cycle Stages , Mice , Mice, Inbred Strains , Molecular Sequence Data , Protozoan Proteins/genetics , Protozoan Proteins/immunology , Protozoan Proteins/isolation & purification , Recombinant Proteins/chemistry , Recombinant Proteins/immunology , Recombinant Proteins/isolation & purification , Recombinant Proteins/metabolism , Sequence Analysis, DNA , Sequence Homology, Amino Acid , Toxoplasma/cytology , Toxoplasma/genetics , Toxoplasma/metabolism , Toxoplasmosis/parasitology , Transcription Factors/chemistry , Transcription Factors/genetics , alpha-Crystallins/chemistry , alpha-Crystallins/genetics , alpha-Crystallins/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...